Kamila_Reid Posted - 1 day ago

$ACRV $AMRN $ENTA LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

mforce12277 Posted - 2 days ago

$ACRV added another 20% today. Long hold.

mforce12277 Posted - 5 days ago

$ACRV added 20% to my position. Buy and hold

Thestocktraderhubzee Posted - 1 week ago

WATCHLIST NOV 14 2024 $ACRV HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $22 Price Target $IMRX Needham Reiterates Buy on Immuneering, Maintains $15 Price Target $VRDN HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Raises Price Target to $34 $CPB Piper Sandler Upgrades Campbell Soup to Overweight, Raises Price Target to $56 $GLPI Mizuho Maintains Neutral on Gaming and Leisure Props, Lowers Price Target to $51

Wigglyick Posted - 1 week ago

$ACRV Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine.

Gwen_Cl Posted - 2 weeks ago

🚨 MYNZ HUGE PR drop incoming before the Nov 13 meeting 🔥 Someone is pushing these dates of upcoming NEWS 3 biggest stock alert channels announced, might consider to add now, who knows. $OMER $NKTR $ACRV $AMRN

KCclean Posted - 1 month ago

$ACRV nice week. $9 next 🍤

briefingcom Posted - 1 month ago

$ACRV: Acrivon Therapeutics announces the company will be presenting data on the ability of its AP3 platform to uniquely enable the clinical development of ACR-368 and the discovery and design of ACR-2316 https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241017080825ACRV&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

mpier Posted - 1 month ago

$ACRV Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium.https://finance.yahoo.com/news/acrivon-therapeutics-present-data-demonstrating-120000946.html

KCclean Posted - 1 month ago

$ACRV revised weekly. Resistance 8/9/10. Nice moves today.

mpier Posted - 1 month ago

$ACRV Great day !

briefingcom Posted - 1 month ago

$ACRV: Acrivon Therapeutics announces that the first patient has been dosed in its Phase 1 clinical trial evaluating ACR-2316, the company’s internally discovered, potent, selective WEE1/PKMYT1 inhibitor, designed by AP3 to overcome the limitations of single-target WEE1 and PKMYT1 inhibitors https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241011080741ACRV&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

KCclean Posted - 1 month ago

$ACRV running out of sellers in the zone?

mpier Posted - 1 month ago

$ACRV Ladenburg Thalmann upgraded their outlook for Acrivon Therapeutics (NasdaqGM:ACRV) from Neutral to Buy.Analyst Price Forecast Suggests 151.85% Upside.https://www.nasdaq.com/articles/ladenburg-thalmann-upgrades-acrivon-therapeutics-acrv

Sstanley14 Posted - 09/24/24

$ACRV just jumped in on this one! Looks ready to breakout.

rickinmiami Posted - 2 months ago

$ACRV Added last week and this week. Strong conviction on this.

Cat19 Posted - 2 months ago

$ACRV In at $7.65

mpier Posted - 2 months ago

$ACRV The lowest ACRV can go is $6.98. If it goes lower than that, ACRV becomes a value play.

mpier Posted - 2 months ago

$ACRV Getting close for me to load up my truck again. Upgrades all over for ACRV on Sept. 16

Bioze Posted - 2 months ago

$ACRV make today's price action make sense given the data release at ESMO on Saturday, you can't...long ACRV!

IN0V8 Posted - 2 months ago

$ACRV Opportunity BMO raises target price to $28 from $25

OpenOutcrier Posted - 2 months ago

$ACRV (+9.3% pre) Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO https://ooc.bz/l/42417

G101SPM Posted - 2 months ago

$ACRV $9.00 bid. DAC (dollar average cost) $9.72 (4.15.24). EXIT $15.00. UPDATE: Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis .

AlertsAndNews Posted - 2 months ago

$ACRV Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis https://www.globenewswire.com/en/news-release/2024/09/14/2946234/0/en/Acrivon-Therapeutics-Reports-Positive-Endometrial-Cancer-Data-from-Ongoing-ACR-368-Registrational-Intent-Phase-2-Study-at-ESMO-Advancement-of-ACR-2316-into-Clinic-Ahead-of-Timeline.html

DonCorleone77 Posted - 2 months ago

$ACRV Acrivon reports data from ongoing ACR-368 registrational intent Phase 2 study Acrivon Therapeutics presented additional clinical data at ESMO from the ongoing registrational intent, multicenter Phase 2 trial of ACR-368 in patients with locally advanced or metastatic, recurrent endometrial cancer. The company has also disclosed that the Investigational New Drug application for its next clinical candidate, ACR-2316, has been cleared by the FDA with initial clinical sites now activated, and first-in-human dosing for the Phase 1 study expected in the fourth quarter of 2024. Importantly, all patients enrolled must have progressed on prior anti-PD-1 therapy, unless ineligible. The data were based on 35 safety-evaluable subjects, of which 23 were efficacy-evaluable with at least one on-treatment scan. Reported a confirmed ORR of 62.5% observed in the cohort of prospectively-selected OncoSignature-positive patients who were efficacy-evaluable. Endometrial cancer is a tumor type that was predicted to be sensitive to ACR-368 by AP3-enabled indication screening before any clinical data was generated. Median duration of response was not yet reached; all responding patients still on therapy. Best overall response in last prior line predominantly progressive disease in confirmed ACR-368 responders. Confirmed responses were observed across molecular and histological subtypes. Demonstrated the ability of the AP3-based ACR-368 OncoSignature assay to prospectively predict patients sensitive to ACR-368 monotherapy based on updated data that showed a clear segregation of responders in the BM+ versus OncoSignature-negative arms. Observed further evidence of sensitization to ACR-368 by ultra-low dose gemcitabine in a proportion of BM- subjects, with an initial disease control in 8 out of 15 subjects, including 1 confirmed complete response. Consistent with past trials and earlier reported data from this trial, the ACR-368 treatment-related adverse events observed were limited, predominantly transient, reversible, mechanism-based hematological AEs, which typically occurred during the first 1-2 cycles of therapy. There was a notable absence of long-lasting myelosuppression, or the typical more severe non-hematological AEs commonly seen with ADCs and chemotherapy. Company conducted a blinded third-party KOL market research study which showed strong interest in the emerging clinical profile of ACR-368 as an important potential therapy in the rapidly evolving treatment landscape of endometrial cancer where second line options are now limited due to anti-PD-1 and chemotherapy having been approved in front line therapy. An estimated ~30K new cases of high-grade, locally advanced or metastatic, recurrent endometrial cancer per year. ~90% of these patients will progress to second line. The recent approval of pembrolizumab plus chemotherapy as a first-line treatment leaves a significant unmet need in the second-line, where the bar from reported chemotherapy efficacy in second-line is an ORR of 14.7% and mPFS of 3.8 months.

F15EAGLE1 Posted - 2 months ago

$ACRV 🙏

StockInvest_us Posted - 2 months ago

Today $ACRV shows BUY signal (TA) for short term. Technical analysis source: https://stockinvest.us/l/kcaWjJW0c1

mpier Posted - 2 months ago

$ACRV I haven't yet figured out why ACRV hasn't exploded yet, but when it does there will be no stopping it. Long!

Stock_Titan Posted - 2 months ago

$ACRV Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis https://www.stocktitan.net/news/ACRV/acrivon-therapeutics-reports-positive-endometrial-cancer-data-from-l9d9pn056f47.html

F15EAGLE1 Posted - 2 months ago

$ACRV